CN112375068B - Terminal alkenyl indole derivative and preparation method thereof - Google Patents

Terminal alkenyl indole derivative and preparation method thereof Download PDF

Info

Publication number
CN112375068B
CN112375068B CN202011218884.XA CN202011218884A CN112375068B CN 112375068 B CN112375068 B CN 112375068B CN 202011218884 A CN202011218884 A CN 202011218884A CN 112375068 B CN112375068 B CN 112375068B
Authority
CN
China
Prior art keywords
compound
hydrogen
substituent
indole derivative
vinyltriethoxysilane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011218884.XA
Other languages
Chinese (zh)
Other versions
CN112375068A (en
Inventor
王亮
李鹏杰
沈洋欢
王泽田
周春妮
郑子昂
肖标
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ezhou Zhengrui Biotechnology Co ltd
Original Assignee
Jianghan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jianghan University filed Critical Jianghan University
Priority to CN202011218884.XA priority Critical patent/CN112375068B/en
Publication of CN112375068A publication Critical patent/CN112375068A/en
Application granted granted Critical
Publication of CN112375068B publication Critical patent/CN112375068B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)

Abstract

The invention provides a terminal alkenyl indole derivative and a preparation method thereof, wherein the method comprises the following steps: reacting a compound I with vinyltriethoxysilane in the presence of an organic solvent and a catalyst to obtain a terminal alkenyl indole derivative shown in a compound II; reaction typeAs shown below, wherein, the substituent R1Selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, methoxy, benzyloxy, halogen, nitro, cyano, ether ester group, phenyl, aldehyde group, allyl, acyloxy and vinyl; substituent R2Selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, allyl, cyclohexyl, cyclopentyl, acyloxy, aldehyde, ether, ester, halogen and cyano; substituent R3Selected from hydrogen, C1-C4 alkyl, phenyl and halogen. The terminal of the alkenyl indole derivative has no substituent, and the method is efficient, simple and convenient and meets the requirement of step economy.
Figure DDA0002761367270000011

Description

Terminal alkenyl indole derivative and preparation method thereof
Technical Field
The invention relates to the technical field of organic synthesis, in particular to a terminal alkenyl indole derivative and a preparation method thereof.
Background
Indole compounds containing an alkenyl structure are an important class of functionalized indole derivatives. They are not only the core building blocks of many drug molecules and pesticide compounds. In addition, the organic molecules also show excellent biological activity due to the alkenyl indole structure. In addition, the alkenyl structure is a very useful functional group to prepare other valuable compounds through various transformations. For example, alkenyl indoles can be converted to carbazole derivatives by olefin cross-metathesis ring-closing reactions; indole derivatives with dihydroxyl functionalization can be prepared by dihydroxylation of olefins; by the epoxidation reaction of an olefin, an epoxidized indole derivative having optical activity can be produced. Accordingly, indoles having an alkenyl structureThe derivatives are star molecules which are of great interest in the fields of medicinal chemistry, biochemistry and the like. Currently, indole compounds having an alkenyl structure can be prepared by the following several methods. (1) The alkynylindoles were subjected to hydrogenation reduction using a palladium on carbon catalyst. (2) Using TiCl4Zn carries out reduction coupling on indole-2-formaldehyde. (2) The witting reaction is carried out using a phosphorus ylide and an indol-2-aldehyde or ketone. These conventional synthesis methods require that functional groups such as alkynyl, halogen or aldehyde groups be placed on the indole ring in advance. The steps of synthesis are increased to a certain extent, and the step economy and atom economy of modern synthetic chemistry are not met. Another useful synthetic method is the direct C-H bond olefination catalyzed by transition metals such as ruthenium, rhodium, palladium, and the like. The method directly activates inert C-H bonds and directly converts the C-H bonds of the indole into alkenyl functional groups. Relatively speaking, the requirements of step economy and atom economy are more satisfied.
However, the prior art is mainly used for the preparation of indole derivatives of non-terminal alkenyl structure, i.e. having various substituents at the terminal of the alkenyl group. Terminal alkene indoles are considered to be a special class of alkenyl indoles, as well as important roles in the terminal alkene structure. Therefore, the development of a synthetic method can directly modify an indole skeleton to obtain an alkenyl indole compound with an end having no substituent, which is of great significance for the preparation of a medicament with an indole structure and the activity research thereof. Therefore, how to prepare an alkenyl indole compound having no substituent at the terminal is a technical problem to be solved urgently.
Disclosure of Invention
The invention aims to provide a terminal alkenyl indole derivative and a preparation method thereof, so that the alkenyl indole derivative without a substituent at the terminal can be successfully prepared, and the method is efficient, simple and convenient and meets the step economy requirement.
In a first aspect of the present invention, there is provided a process for the preparation of a terminal alkenyl indole derivative, the process comprising:
reacting a compound I with vinyltriethoxysilane in the presence of an organic solvent and a catalyst to obtain a terminal alkenyl indole derivative shown in a compound II;
Figure BDA0002761367250000021
wherein, the substituent R1Selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, methoxy, benzyloxy, halogen, nitro, cyano, ether ester group, phenyl, aldehyde group, allyl, acyloxy and vinyl;
substituent R2Selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, allyl, cyclohexyl, cyclopentyl, acyloxy, aldehyde, ether, ester, halogen and cyano;
substituent R3Selected from hydrogen, C1-C4 alkyl, phenyl and halogen.
Further, the molar weight ratio of the compound I to the vinyltriethoxysilane is 1: (2-4).
Further, the reaction temperature is 80-120 ℃, and the reaction time is 12-24 h.
Further, the catalyst comprises Cu (OAc)2AgF and [ RhCp Cl ]2]2
Further, the molar weight ratio of the catalyst to the compound I is Cu (OAc)2:AgF:[RhCp*Cl2]2: compound I ═ (2-3): (2-3): (0.01-0.1): 1.
further, the organic solvent is one or more of 1, 2-dichloroethane DCE, dimethylformamide DMF, acetonitrile and DMSO.
Further, the organic solvent is a mixed solvent of 1, 2-dichloroethane DCE and dimethylformamide DMF, and the volume ratio of the 1, 2-dichloroethane DCE to the dimethylformamide DMF is (1-10): 1.
further, after the reaction is completed, separation and purification are carried out, wherein the separation and purification comprises the following steps: and cooling the product obtained by the reaction to room temperature, concentrating to obtain a crude product, and then separating and purifying the crude product by silica gel column chromatography to obtain the pure terminal alkenyl indole derivative.
Further, in the separation and purification by silica gel column chromatography, the organic solvent used is petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is (2-10): 1.
in a second aspect of the present invention, there is provided a terminal alkenyl indole derivative, wherein the structural formula of the terminal alkenyl indole derivative is as follows:
Figure BDA0002761367250000031
wherein, the substituent R1Selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, methoxy, benzyloxy, halogen, nitro, cyano, ether ester group, phenyl, aldehyde group, allyl, acyloxy and vinyl;
substituent R2Selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, allyl, cyclohexyl, cyclopentyl, acyloxy, aldehyde, ether, ester, halogen and cyano;
substituent R3Selected from hydrogen, C1-C4 alkyl, phenyl and halogen;
wherein, the substituent R3When it is hydrogen, R2Is selected from alkoxy of C1-C4, acyloxy, aldehyde group and cyano.
One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:
the present inventors have found that a terminal alkenylindole derivative represented by compound II can be obtained by reacting compound I with vinyltriethoxysilane in an organic solvent under a catalyst condition, and have developed a method for synthesizing an alkenylindole derivative having no substituent at the terminal. The method is not only efficient and simple, but also meets the economic requirement of the steps.
Drawings
In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings needed to be used in the description of the embodiments are briefly introduced below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and it is obvious for those skilled in the art to derive other drawings without creative efforts.
FIG. 1 is an H NMR spectrum of a terminal alkenyl indole derivative prepared in example 19 of the present invention;
FIG. 2 is a C NMR spectrum of a terminal alkenyl indole derivative prepared in example 19 of the present invention.
Detailed Description
The present invention will be described in detail below with reference to specific embodiments and examples, and the advantages and various effects of the present invention will be more clearly apparent therefrom. It will be understood by those skilled in the art that these specific embodiments and examples are for the purpose of illustrating the invention and are not to be construed as limiting the invention.
Throughout the specification, unless otherwise specifically noted, terms used herein should be understood as having meanings as commonly used in the art. Accordingly, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. If there is a conflict, the present specification will control.
Unless otherwise specifically stated, various raw materials, reagents, instruments, equipment and the like used in the present invention are commercially available or can be prepared by existing methods.
In order to solve the technical problems, the embodiment of the invention provides the following general ideas:
according to an exemplary embodiment of the present invention, there is provided a method for preparing a terminal alkenyl indole derivative, the method including:
reacting a compound I with vinyltriethoxysilane in the presence of an organic solvent and a catalyst to obtain a terminal alkenyl indole derivative shown in a compound II;
Figure BDA0002761367250000041
wherein, the substituent R1Selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, methoxy, benzyloxy, halogen, nitro, cyano, ether ester group, phenyl, aldehyde group, allyl, acyloxy and vinyl;
substituent R2Selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, allyl, cyclohexyl, cyclopentyl, acyloxy, aldehyde, ether, ester, halogen and cyano;
substituent R3Selected from hydrogen, C1-C4 alkyl, phenyl and halogen.
The present applicant has found that a terminal alkenylindole derivative represented by compound II can be obtained by reacting compound I with vinyltriethoxysilane in the presence of an organic solvent and a catalyst, and has developed a method for synthesizing an alkenylindole derivative having no substituent at the terminal by using vinyltriethoxysilane as a alkenylating agent. The method is not only efficient and simple, but also meets the economic requirement of the steps.
As a preferred embodiment, the molar weight ratio of said compound I and said vinyltriethoxysilane is 1: (2-4). Too high or too low of this ratio is detrimental to the reaction;
in a preferred embodiment, the reaction temperature is 80-120 ℃, and the reaction time is 12-24 h. The reaction temperature is too low or too high, which is not favorable for the reaction to be carried out or the reaction to be completed.
As a preferred embodiment, the catalyst comprises Cu (OAc)2AgF and [ RhCp Cl ]2]2
In a preferred embodiment, the molar weight ratio of the catalyst to the compound I is Cu (OAc)2:AgF:
[RhCp*Cl2]2: compound I ═ (2-3): (2-3): (0.01-0.1): 1. this ratio is either too low or too high to allow complete reaction to the terminal alkenyl indole derivative of compound II.
As a preferred embodiment, the organic solvent is one or more of 1, 2-dichloroethane DCE, dimethylformamide DMF, acetonitrile and DMSO. When the organic solvent is a mixed solvent of 1, 2-dichloroethane DCE and dimethylformamide DMF, the volume ratio of the 1, 2-dichloroethane DCE to the dimethylformamide DMF is (1-10): 1.
as a preferred embodiment, after the reaction is completed, separation and purification are performed, and the separation and purification include: and cooling the product obtained by the reaction to room temperature, concentrating to obtain a crude product, and then separating and purifying the crude product by silica gel column chromatography to obtain the pure terminal alkenyl indole derivative. In the separation and purification by silica gel column chromatography, the organic solvent used is petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is (2-10): 1.
according to another exemplary embodiment of the present invention, the terminal alkenyl indole derivative has a structural formula as follows:
Figure BDA0002761367250000051
wherein, the substituent R1Selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, methoxy, benzyloxy, halogen, nitro, cyano, ether ester group, phenyl, aldehyde group, allyl, acyloxy and vinyl;
substituent R2Selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, allyl, cyclohexyl, cyclopentyl, acyloxy, aldehyde, ether, ester, halogen and cyano;
substituent R3Selected from hydrogen, C1-C4 alkyl, phenyl and halogen;
wherein, the substituent R3When it is hydrogen, R2Is selected from alkoxy of C1-C4, acyloxy, aldehyde group and cyano.
The alkenyl indole derivative with the terminal in the structural general formula of the alkenyl indole derivative has no substituent at the terminal, and has important significance for preparing a medicament with an indole structure and researching the activity of the medicament.
The following will describe in detail a method for preparing a terminal alkenyl indole derivative of the present application with reference to examples and experimental data.
Example 1
Figure BDA0002761367250000052
In this embodiment: r1Is hydrogen; r2Is methyl; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-1(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: 88 percent.
Compound II-1 was tested:
melting point: 99-100 deg.C
1H NMR(400MHz,CDCl3)δ8.77(d,J=4.8Hz,2H),8.27(d,J=7.9Hz,1H),7.57(d,J=7.2Hz,1H),7.31–7.21(m,2H),7.11–7.02(m,2H),5.50–5.38(m,2H),2.44(s,3H).
13C NMR(100MHz,CDCl3)δ158.18,158.09,136.20,133.90,130.67,128.84,123.89,121.73,118.78,116.76,116.68,115.41,113.66,10.26.
HRMS m/z:calcd forC15H14N3 +[M+H+]236.1182,found 236.1181.
Example 2
Figure BDA0002761367250000061
In this embodiment: r1Is methyl; r2Is methyl; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-2(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: and 69 percent.
Compound II-2 was tested:
melting point: 64-65 deg.C
1H NMR(400MHz,CDCl3)δ8.75(d,J=4.8Hz,2H),8.17(d,J=8.5Hz,1H),7.35(s,1H),7.12–7.00(m,3H),5.49–5.39(m,2H),2.47(s,3H),2.41(s,3H).
13C NMR(100MHz,CDCl3)δ158.25,158.02,134.50,133.99,131.11,130.91,129.07,125.33,118.64,116.48,116.34,115.26,113.55,21.40,10.27.
HRMS m/z:calcd for C16H16N3 +[M+H+]250.1339,found 250.1340.
Example 3
Figure BDA0002761367250000071
In this embodiment: r1Is bromine; r2Is methyl; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-3(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: 79 percent.
Compound II-3 was tested:
melting point: 98-99 deg.C
1H NMR(400MHz,CDCl3)δ8.77(d,J=4.8Hz,2H),8.16(d,J=8.8Hz,1H),7.68(d,J=1.9Hz,1H),7.34(dd,J=8.8,2.0Hz,1H),7.14(t,J=4.8Hz,1H),7.04(dd,J=17.7,11.5Hz,1H),5.51(dd,J=11.5,1.5Hz,1H),5.45(dd,J=17.7,1.5Hz,1H),2.39(s,3H).
13C NMR(100MHz,CDCl3)δ160.84,158.63,157.93,137.26,133.61,131.80,131.46,128.38,126.61,124.33,121.62,121.12,120.77,118.29,111.61,51.67.
HRMS m/z:calcd for C15H13BrN3 +[M+H+]314.0287,found 314.0288.
Example 4
Figure BDA0002761367250000072
In this embodiment: r1Is chlorine; r2A methyl group; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-4(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: 72 percent.
Compound II-4 was tested:
melting point: 120 ℃ to 121 DEG C
1H NMR(400MHz,CDCl3)δ8.77(d,J=4.8Hz,2H),8.21(d,J=8.8Hz,1H),7.52(d,J=2.0Hz,1H),7.21(dd,J=8.8,2.1Hz,1H),7.14(t,J=4.8Hz,1H),7.09–6.99(m,1H),5.51(dd,J=11.5,1.6Hz,1H),5.45(dd,J=17.7,1.6Hz,1H),2.39(s,3H).
13C NMR(100MHz,CDCl3)δ158.15,157.93,135.26,134.45,131.93,128.67,127.30,123.85,118.33,117.50,117.03,115.04,114.63,10.19.
HRMS m/z:calcd for C15H13ClN3 +[M+H+]270.0793,found 270.0797.
Example 5
Figure BDA0002761367250000081
In this embodiment: r1Is methoxy; r2Is methyl; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-5(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: and 63 percent.
Compound II-5 was tested:
melting point: 108 temperature 109 deg.C
1H NMR(400MHz,CDCl3)δ8.74(d,J=4.8Hz,2H),8.24(d,J=9.0Hz,1H),7.18–6.97(m,3H),6.91(dd,J=9.0,2.6Hz,1H),5.54–5.39(m,2H),3.89(s,3H),2.41(s,3H).
13C NMR(100MHz,CDCl3)δ158.16,158.01,155.44,134.62,131.46,131.05,129.14,116.51,116.43,115.23,114.95,112.88,101.05,55.74,10.37.
HRMS m/z:calcd for C16H16N3O+[M+H+]266.1288,found 266.1288
Example 6
Figure BDA0002761367250000091
In this embodiment: r1Is cyano;R2Is methyl; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-6(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: 66 percent.
Compound II-6 was tested:
melting point: 173 ℃ and 174 DEG C
1H NMR(400MHz,CDCl3)δ8.83(d,J=4.8Hz,2H),8.29(dd,J=8.7,0.6Hz,1H),7.90(dd,J=1.6,0.5Hz,1H),7.50(dd,J=8.7,1.6Hz,1H),7.24(t,J=4.8Hz,1H),7.02(dd,J=17.7,11.6Hz,1H),5.56(dd,J=11.6,1.5Hz,1H),5.50(dd,J=17.7,1.5Hz,1H),2.44(s,3H).
13C NMR(100MHz,CDCl3)δ158.4,158.3,157.6,137.8,136.2,130.6,128.0,126.7,123.9,120.4,118.7,117.9,114.8,114.5,104.8,10.1.
HRMS m/z:calcd for C16H13N4 +[M+H+]261.1135,found 261.1138.
Example 7
Figure BDA0002761367250000092
In this embodiment: r1Is nitro; r2Is methyl; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-7(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), and the mixture was reacted at 90 ℃ C. and checked by TLC (thin layer chromatography) until the reaction was complete. IntoPost-treatment and purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a yellow solid, yield: 56 percent.
Compound II-7 was tested:
melting point: 109 ℃ and 110 DEG C
1H NMR(400MHz,CDCl3)δ8.85(d,J=4.8Hz,2H),8.50(d,J=2.2Hz,1H),8.28(d,J=9.2Hz,1H),8.15(dd,J=9.2,2.3Hz,1H),7.27(t,J=4.8Hz,1H),7.02(dd,J=17.8,11.6Hz,1H),5.58(dd,J=11.6,1.4Hz,1H),5.53(dd,J=17.7,1.4Hz,1H),2.48(s,3H).
13C NMR(100MHz,CDCl3)δ158.44,157.81,142.96,139.02,136.99,130.33,127.93,119.02,118.94,118.08,115.85,115.46,113.75,10.17.
HRMS m/z:calcd for C15H13N4O2 +[M+H+]281.1033,found 281.1039.
Example 8
Figure BDA0002761367250000101
In this embodiment: r1Is methyl; r2Is methyl; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-8(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: 71 percent.
Compound II-8 was tested:
melting point: 145- & ltSUB & gt 146- & lt/SUB & gt
1H NMR(400MHz,CDCl3)δ8.79(d,J=4.8Hz,2H),8.10–8.01(m,1H),7.45(d,J=8.0Hz,1H),7.11(t,J=4.8Hz,1H),7.08–6.97(m,2H),5.46–5.37(m,2H),2.48(s,3H),2.42(s,3H).
13C NMR(101MHz,CDCl3)δ158.11,136.59,133.89,133.27,128.84,128.56,123.30,118.46,116.68,116.08,115.49,113.52,22.06,10.32.
HRMS m/z:calcd for C16H16N3 +[M+H+]250.1339,found 250.1346.
Example 9
Figure BDA0002761367250000111
In this embodiment: r1Is fluorine; r2Is methyl; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-9(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: 53 percent.
Compound II-9 was tested:
melting point: 126 ℃ and 127 DEG C
1H NMR(400MHz,CDCl3)δ8.77(d,J=4.8Hz,2H),8.06(dd,J=11.0,2.4Hz,1H),7.46(dd,J=8.6,5.5Hz,1H),7.13(t,J=4.8Hz,1H),7.09–6.95(m,2H),5.46(dd,J=11.5,1.6Hz,1H),5.41(dd,J=17.7,1.6Hz,1H),2.41(s,3H).
13C NMR(100MHz,CDCl3)δ162.2,159.8,158.2,158.1,136.4,136.2,134.4,134.4,128.9,127.2,119.4,119.3,117.0,116.54,115.3,110.2,109.9,101.3,101.0,10.3.
HRMS m/z:calcd for C15H13FN3 +[M+H+]254.1088,found 254.1090.
Example 10
Figure BDA0002761367250000112
In this embodiment: r1Is chlorine; r2Is methyl; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-10(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: and 64 percent.
Compound II-10 was tested:
melting point: 106 ℃ C. & 107 ℃ C. (Perkin Elmer)
1H NMR(400MHz,CDCl3)δ8.78(d,J=4.8Hz,2H),8.33(d,J=1.8Hz,1H),7.46(d,J=8.4Hz,1H),7.20(dd,J=8.4,1.8Hz,1H),7.14(t,J=4.8Hz,1H),7.03(dd,J=17.7,11.5Hz,1H),5.49(dd,J=11.5,1.5Hz,1H),5.44(dd,J=17.7,1.4Hz,1H),2.41(s,3H).
13C NMR(101MHz,CDCl3)δ158.18,157.87,136.39,134.59,129.64,129.24,128.66,122.27,119.51,117.11,117.08,115.11,113.99,10.21.
HRMS m/z:calcd for C15H13ClN3 +[M+H+]270.0793,found 270.0794.
Example 11
Figure BDA0002761367250000121
In this embodiment: r1Is bromine; r2Is methyl;R3is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-11(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: 61 percent.
Compound II-11 was tested:
melting point: 79-80 deg.C
1H NMR(400MHz,CDCl3)δ8.78(d,J=4.8Hz,2H),8.48(d,J=1.6Hz,1H),7.41(d,J=8.3Hz,1H),7.33(dd,J=8.3,1.7Hz,1H),7.13(t,J=4.8Hz,1H),7.02(dd,J=17.7,11.5Hz,1H),5.49(dd,J=11.5,1.5Hz,1H),5.44(dd,J=17.7,1.5Hz,1H),2.40(s,3H).
13C NMR(100MHz,CDCl3)δ158.17,157.80,136.68,134.49,129.54,128.61,124.89,119.88,117.45,117.21,117.10,116.82,115.09,10.17.
HRMS m/z:calcd for C15H13BrN3 +[M+H+]314.0287,found 314.0286.
Example 12
Figure BDA0002761367250000131
In this embodiment: r1Is hydrogen; r2Is ethyl; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-12(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooling the mixture to the room temperature,concentrating under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a yellow solid, yield: 65 percent.
Compound II-12 was tested:
1H NMR(400MHz,CDCl3)δ8.75(d,J=4.8Hz,2H),8.30–8.22(m,1H),7.64–7.57(m,1H),7.31–7.19(m,2H),7.08(t,J=4.8Hz,1H),7.04–6.94(m,1H),5.46–5.36(m,2H),2.91(q,J=7.6Hz,2H),1.33(dd,J=7.9,7.2Hz,3H).
13C NMR(101MHz,CDCl3)δ158.13,158.06,136.40,133.45,129.76,128.61,123.79,121.89,121.66,118.84,116.78,115.90,113.70,18.02,15.32.
HRMS m/z:calcd for C16H16N3 +[M+H+]250.1339,found 250.1346.
example 13
Figure BDA0002761367250000132
In this embodiment: r1Is hydrogen; r2Is butyl; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-13(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a yellow solid, yield: 38 percent.
Compound II-13 was tested:
melting point: 86-87 deg.C
1H NMR(400MHz,CDCl3)δ8.77(d,J=4.8Hz,2H),8.24(d,J=8.2Hz,1H),7.60(d,J=7.7Hz,1H),7.24(dt,J=20.1,7.1Hz,2H),7.11(t,J=4.8Hz,1H),6.98(dd,J=17.6,11.7Hz,1H),5.39(dd,J=14.8,7.9Hz,2H),2.92–2.84(m,2H),1.70(dd,J=15.5,8.1Hz,2H),1.48(dd,J=14.9,7.4Hz,2H),0.97(t,J=7.3Hz,3H).
13C NMR(100MHz,CDCl3)δ158.2,158.2,136.5,133.7,130.2,128.6,123.8,121.7,120.8,119.1,116.9,116.0,113.6,33.1,24.6,23.1,14.1.
HRMS m/z:calcd for C18H20N3 +[M+H+]278.1652,found 278.1659.
Example 14
Figure BDA0002761367250000141
In this embodiment: r1Is phenyl; r2Is isopropyl; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-14(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: 42 percent.
Compound II-14 was tested:
melting point: 78-79 deg.C
1H NMR(400MHz,CDCl3)δ8.78(d,J=4.8Hz,2H),8.21(d,J=8.2Hz,1H),7.80(d,J=7.9Hz,1H),7.27–7.21(m,1H),7.20–7.16(m,1H),7.13(t,J=4.8Hz,1H),6.98(dd,J=17.7,11.4Hz,1H),5.42(dd,J=11.4,1.7Hz,1H),5.25(dd,J=17.7,1.7Hz,1H),3.56–3.45(m,1H),1.49(d,J=7.1Hz,6H).
13C NMR(100MHz,CDCl3)δ158.2,158.1,137.0,133.0,128.7,128.4,125.5,123.4,121.2,120.8,117.5,117.0,113.6,26.1,22.7.
HRMS m/z:calcd for C17H18N3 +[M+H+]264.1495,found 264.1496.
Example 15
Figure BDA0002761367250000151
In this embodiment: r1Is hydrogen; r2Is allyl; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-15(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: 51 percent.
Compound II-15 was tested:
melting point: 85-86 deg.C
1H NMR(400MHz,CDCl3)δ8.78(d,J=4.8Hz,2H),8.29(dd,J=8.3,0.5Hz,1H),7.57(dd,J=7.7,0.5Hz,1H),7.28(dd,J=11.4,4.0Hz,1H),7.21(dd,J=7.6,7.2Hz,1H),7.11(td,J=4.8,0.6Hz,1H),7.02(dd,J=17.7,11.5Hz,1H),6.16–6.01(m,1H),5.53–5.38(m,2H),5.15–5.03(m,2H),3.69–3.60(m,2H).
13C NMR(100MHz,CDCl3)δ158.10,136.76,136.27,134.82,130.04,128.51,123.88,121.80,119.13,116.87,116.79,116.68,115.45,113.80,29.29.
HRMS m/z:calcd for C17H16N3 +[M+H+]262.1339,found 262.1346.
Example 16
Figure BDA0002761367250000152
In this embodiment: r1Is hydrogen; r2Is an ester group; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-16(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: 59 percent.
Compound II-16 was tested:
melting point: 112 ℃ and 113 DEG C
1H NMR(400MHz,CDCl3)δ8.77(d,J=4.8Hz,2H),8.31(d,J=8.3Hz,1H),7.63(d,J=7.8Hz,1H),7.34–7.26(m,6H),7.23(dd,J=8.1,0.8Hz,1H),7.12(t,J=4.8Hz,1H),7.04(dd,J=17.7,11.5Hz,1H),5.64(dd,J=17.7,1.5Hz,1H),5.48(dd,J=11.5,1.5Hz,1H),5.15(s,2H),3.94(s,2H).
13C NMR(100MHz,CDCl3)δ171.41,158.08,157.99,136.32,136.02,135.86,129.68,128.45,128.42,128.10,128.09,124.08,122.10,119.18,118.03,117.05,114.02,111.64,66.65,31.57.
HRMS m/z:calcd for C23H20N3O2 +[M+H+]370.1550,found 370.1558.
Example 17
Figure BDA0002761367250000161
In this embodiment: r1Is hydrogen; r2Is a carboxyl group; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-17(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: 50 percent.
Compound II-17 was tested:
melting point: 102 ℃ to 103 DEG C
1H NMR(400MHz,CDCl3)δ8.77(d,J=4.8Hz,2H),8.34(d,J=8.4Hz,1H),7.39(d,J=7.8Hz,1H),7.31–7.27(m,1H),7.27–7.20(m,1H),7.13(t,J=4.8Hz,1H),7.04(dd,J=17.8,11.7Hz,1H),5.70(dd,J=17.8,1.6Hz,1H),5.46(dd,J=11.7,1.6Hz,1H),2.41(s,3H).
13C NMR(101MHz,CDCl3)δ168.74,158.17,157.83,133.94,132.09,126.78,126.59,124.58,122.93,122.39,117.40,117.20,116.80,114.42,20.80.
HRMS m/z:calcd for C16H14N3O2 +[M+H+]280.1081,found 280.1088.
Example 18
Figure BDA0002761367250000171
In this embodiment: r1Is hydrogen, R2Is bromine; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-18(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: and 47 percent.
Compound II-18 was tested:
melting point: 73-74 deg.C
1H NMR(400MHz,CDCl3)δ8.82(d,J=4.8Hz,2H),8.19–8.14(m,1H),7.65–7.57(m,1H),7.35–7.27(m,2H),7.20(t,J=4.8Hz,1H),6.95(dd,J=17.8,11.8Hz,1H),5.97(dd,J=17.8,1.2Hz,1H),5.57(dd,J=11.8,1.2Hz,1H).
13C NMR(100MHz,CDCl3)δ158.36,157.62,135.82,133.78,128.88,126.78,124.94,122.71,119.62,119.41,117.76,113.53,97.86.
HRMS m/z:calcd for C14H11BrN3 +[M+H+]300.0131,found 300.0136.
Example 19
Figure BDA0002761367250000172
In this embodiment: r1Is hydrogen, R2Is an aldehyde group; r3Is hydrogen.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-19(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: 42 percent.
Compound II-19 was tested:
melting point: 81-82 deg.C
1H NMR(400MHz,CDCl3)δ10.18(s,1H),8.87(d,J=4.8Hz,2H),8.47(dd,J=7.5,1.7Hz,1H),8.24–8.13(m,1H),7.41–7.34(m,2H),7.31(t,J=4.9Hz,1H),7.28–7.22(m,1H),5.78(dd,J=11.3,1.4Hz,1H),5.68(dd,J=17.4,1.4Hz,1H).
13C NMR(100MHz,CDCl3)δ187.6,158.5,157.2,148.6,136.0,126.4,126.2,125.3,124.8,124.2,122.0,118.7,118.5,113.7.
HRMS m/z:calcd for C15H12N3O+[M+H+]250.0975,found 250.0972.
Example 20
Figure BDA0002761367250000181
In this embodiment: r1Is hydrogen, R2Is methyl, R3Is phenyl.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-20(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: 72 percent.
Compound II-20 test: r3
Melting point: 95-96 deg.C
1H NMR(400MHz,CDCl3)δ8.99(d,J=2.4Hz,2H),8.37–8.28(m,1H),7.64–7.57(m,3H),7.56–7.51(m,2H),7.49–7.43(m,1H),7.31(ddd,J=8.3,7.2,1.4Hz,1H),7.27–7.23(m,1H),7.11(dd,J=17.7,11.6Hz,1H),5.57–5.42(m,2H),2.46(s,3H).
13C NMR(100MHz,CDCl3)δ157.2,156.0,136.2,134.1,134.0,130.7,129.6,129.4,128.9,128.6,126.6,123.9,121.8,118.8,116.8,115.5,113.8,29.7,10.3.
HRMS m/z:calcd for C21H18N3 +[M+H+]312.1495,found 312.1492.
Example 21
Figure BDA0002761367250000191
In this embodiment: r1Is hydrogen, R2Is methyl, R3Is bromine.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-21(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%) 1, 2-dichloroethane (2mL), the mixture was reacted at 90 ℃ and TLC (by thin layer chromatography) was checked to completion. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: and 47 percent.
Compound II-21 was tested:
melting point: 70-71 deg.C
1H NMR(400MHz,CDCl3)δ8.77(d,J=4.8Hz,2H),8.26(dd,J=8.6,0.6Hz,1H),7.61–7.51(m,1H),7.31–7.20(m,2H),7.05(dd,J=18.2,12.1Hz,1H),5.50–5.39(m,2H),2.44(s,3H).
13C NMR(100MHz,CDCl3)δ158.2,158.1,136.2,133.9,130.7,128.8,123.9,121.7,118.8,116.8,116.7,115.4,113.7,10.3.
HRMS m/z:calcd for C15H13BrN3 +[M+H+]314.0287,found 314.0274.
Example 22
Figure BDA0002761367250000192
In this embodiment: r1Is hydrogen, R2Is methyl, R3Is methyl.
The method comprises the following steps: to a 35mL sealed tube with a branch, Compound I-22(0.2mmol), vinyltriethoxysilane (0.6mmol), Cu (OAc)2(0.4mmol),AgF(0.4mmol),[RhCp*Cl2]2(2 mol%), 1, 2-dichloroethane (2mL), the mixture was left at 90 deg.CThe reaction was checked by TLC (thin layer chromatography) until the reaction was complete. Carrying out post-treatment purification: cooled to room temperature and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography [ V (petroleum ether): v (ethyl acetate) ═ 5:1, to give the pure product as a white solid, yield: 58 percent.
Compound II-22 was tested:
melting point: 60-61 deg.C
1H NMR(400MHz,CDCl3)δ8.60(s,2H),8.14(d,J=7.9Hz,1H),7.57(d,J=7.6Hz,1H),7.29–7.18(m,2H),7.01(dd,J=17.6,11.6Hz,1H),5.51–5.37(m,2H),2.44(s,3H),2.33(s,3H).
13C NMR(100MHz,CDCl3)δ158.2,156.3,136.3,133.7,130.4,128.5,126.2,123.7,121.4,118.7,116.7,114.8,113.1,15.1,10.2.
HRMS m/z:calcd for C16H16N3 +[M+H+]250.1339,found 250.1345.
Finally, it should also be noted that the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
While preferred embodiments of the present invention have been described, additional variations and modifications in those embodiments may occur to those skilled in the art once they learn of the basic inventive concepts. Therefore, it is intended that the appended claims be interpreted as including preferred embodiments and all such alterations and modifications as fall within the scope of the invention.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.

Claims (7)

1. A method for preparing a terminal alkenyl indole derivative, comprising:
reacting a compound I with vinyltriethoxysilane in the presence of an organic solvent and a catalyst to obtain a terminal alkenyl indole derivative represented by a compound II, wherein the reaction formula is as follows:
Figure DEST_PATH_IMAGE002
wherein, the substituent R1Selected from hydrogen, C1-C4 alkyl, C1-C4 alkoxy, benzyloxy, halogen, nitro, cyano, ether ester group, phenyl, aldehyde group, allyl, acyloxy and vinyl;
substituent R2Selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, allyl, cyclohexyl, cyclopentyl, acyloxy, aldehyde, ether, ester, halogen and cyano;
substituent R3Selected from hydrogen, C1-C4 alkyl, phenyl and halogen; the catalyst is Cu (OAc)2AgF and [ RhCp Cl ]2]2
The molar weight ratio of the catalyst to the compound I is Cu (OAc)2:AgF:[RhCp*Cl2]2: compound I = (2-3): (2-3): (0.01-0.1): 1.
2. the method according to claim 1, wherein the molar weight ratio of the compound I to the vinyltriethoxysilane is 1: (2-4).
3. The preparation method according to claim 1, wherein the reaction temperature is 80-120 ℃ and the reaction time is 12-24 h.
4. The method according to claim 1, wherein the organic solvent is at least one of 1, 2-Dichloroethane (DCE), Dimethylformamide (DMF), acetonitrile and DMSO.
5. The preparation method according to claim 4, wherein the organic solvent is a mixed solvent of 1, 2-dichloroethane DCE and dimethylformamide DMF, and the volume ratio of the 1, 2-dichloroethane DCE to the dimethylformamide DMF is (1-10): 1.
6. the preparation method according to claim 1, wherein the compound I and vinyltriethoxysilane are reacted in an organic solvent and under the condition of a catalyst to obtain the terminal alkenyl indole derivative represented by compound II, which specifically comprises:
reacting a compound I with vinyl triethoxysilane in the presence of an organic solvent and a catalyst to obtain a reaction material;
cooling the reaction material to room temperature, and concentrating to obtain a crude product;
and (3) separating and purifying the crude product by silica gel column chromatography to obtain the pure terminal alkenyl indole derivative.
7. The preparation method according to claim 6, wherein the organic solvent used in the separation and purification by silica gel column chromatography is petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is (2-10): 1.
CN202011218884.XA 2020-11-04 2020-11-04 Terminal alkenyl indole derivative and preparation method thereof Active CN112375068B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011218884.XA CN112375068B (en) 2020-11-04 2020-11-04 Terminal alkenyl indole derivative and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011218884.XA CN112375068B (en) 2020-11-04 2020-11-04 Terminal alkenyl indole derivative and preparation method thereof

Publications (2)

Publication Number Publication Date
CN112375068A CN112375068A (en) 2021-02-19
CN112375068B true CN112375068B (en) 2022-03-08

Family

ID=74579211

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011218884.XA Active CN112375068B (en) 2020-11-04 2020-11-04 Terminal alkenyl indole derivative and preparation method thereof

Country Status (1)

Country Link
CN (1) CN112375068B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113045549B (en) * 2021-03-16 2022-12-27 江汉大学 Pyrrole ethylene derivative and preparation method thereof
CN115636812A (en) * 2022-09-30 2023-01-24 江汉大学 Terminal alkenyl indoline derivative and preparation method thereof
CN115650953A (en) * 2022-09-30 2023-01-31 江汉大学 Terminal alkenyl indole derivative and preparation method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106928201B (en) * 2017-02-22 2019-08-23 江汉大学 The method for synthesizing 2- vinyl indole derivatives

Also Published As

Publication number Publication date
CN112375068A (en) 2021-02-19

Similar Documents

Publication Publication Date Title
CN112375068B (en) Terminal alkenyl indole derivative and preparation method thereof
CN106928201B (en) The method for synthesizing 2- vinyl indole derivatives
Samakkanad et al. IBX/I2-Mediated reaction of sodium arenesulfinates with alkenes: facile synthesis of β-keto sulfones
CN113307790B (en) Preparation method of 3-quinolyl-5-trifluoromethyl substituted 1,2, 4-triazole compound
CN109232363B (en) Synthetic method of 3-selenocyanoindole compound
CN110256443B (en) Indole derivative and preparation method thereof
CN109134460B (en) Synthesis method of beta-carboline compound
Luo et al. Total syntheses of melinonine-E and strychnoxanthine: Evolution of the synthetic strategy enabled by novel method development
McGonagle et al. A three-step tandem process for the synthesis of bicyclic γ-lactams
CN110483507A (en) A kind of synthetic method of naphtho- [1 ', 2 ': 4,5] imidazo [1,2-a] pyridine compounds and their
WO2022156025A1 (en) SYNTHESIS METHOD FOR 4-(2,2,2-TRICHLOROETHYL)-β-LACTAM DERIVATIVE
CN108084082B (en) Method for synthesizing [ b ] -cyclized indole derivatives
CN108929215B (en) Synthesis method of cis-alpha-halogenated alpha, beta-unsaturated ketone compound
CN108690031B (en) Synthetic method of furo [3,4-c ] quinoline/furo [3,4-c ] coumarin compound
CN111004164B (en) Preparation method of polysubstituted 2-aryl indole derivative
CN109438439B (en) Tetrahydroisoquinolino 1,2, 4-triazole derivative and preparation method thereof
EP1731509A1 (en) Process for producing nitrogenous 5-membered cyclic compound
CN109988113B (en) Synthesis method of [60] fullerene tetrahydroquinoline derivative
CN108623503B (en) Green preparation method of vinyl sulfone derivative in water phase
CN111285846B (en) 2- (2-indolyl) -acetate derivative and synthesis method thereof
CN111423370B (en) Preparation method of 3-alkoxy-4-quinolinone derivative
CN114085210B (en) Quinoline-substituted indole derivative and preparation method and application thereof
CN110117246B (en) Preparation method of 3-position indolylated cyclohexenone compound
CN115286628B (en) Preparation method of indolo [2,1a ] isoquinoline compound
CN107459530A (en) A kind of 1,3 isoquinolin derovatives of novel silicon base substitution and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230912

Address after: No. 503, Floor 5, Building A15, East Lake High tech Creative City, south of Phoenix Avenue, wutong Lake New District, Liangzihu District, Ezhou City, Hubei Province, 436000

Patentee after: Ezhou Zhengrui Biotechnology Co.,Ltd.

Address before: 430056 No. 8 Xinjiang road, Zhuankou economic and Technological Development Zone, Wuhan, Hubei

Patentee before: JIANGHAN University